| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
